Large gap with delayed quotes
|
Last quote
04/25/2026
-
02:00:00
|
Bid
04/27/2026 -
14:56:24
|
Bid Volume |
Ask
04/27/2026 -
14:56:24
|
Ask Volume |
|---|---|---|---|---|
|
19.87
+0.42
(
+2.16% )
|
19.50
|
100 |
21.97
|
100 |
Analysis date: 24.04.2026
Global Evaluation
Negativ
Negativ
The stock is classified in the negative zone since 21.04.2026.
Interest
Very weak
Very weak
One star since 21.04.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 21.04.2026 at a price of 20.13.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded above its moving average since 17.04.2026.
4wk Rel Perf
-14.53%
-14.53%
The four-week dividend-adjusted underperformance versus SP500 is 14.53%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 0.96%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.57%.
Mkt Cap in $bn
3.15
3.15
With a market capitalization between $2 & $8bn, DENALI THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
0.57
0.57
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
-16.21
-16.21
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
9.22%
9.22%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
17
17
Over the last seven weeks, an average of 17 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
168
168
For 1% of index variation, the stock varies on average by 1.68%.
Correlation
0.39
0.39
Stock movements are strongly independent of index variations.
Value at Risk
8.36
8.36
The value at risk is estimated at USD 8.36. The risk is therefore 42.06%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
27.11.2020
27.11.2020